Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients

References

• Leontiadias GI, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal bleeding. Gastroenterol Clin North Am 2009;38:199-213
   PubMedGoogle Scholar
• Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am 2009;38:245-65
   PubMed Web of Science ®Google Scholar
• Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007;64:1396-400
   PubMed Web of Science ®Google Scholar
• Barkun AN, Bardou M, Kuipers EK, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13
   PubMed Web of Science ®Google Scholar
• Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 2010;38:2222-8
   PubMed Web of Science ®Google Scholar
• Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm 2005;62(Suppl 2):S4-10
   Google Scholar
• Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002;36:1929-37
   PubMed Web of Science ®Google Scholar
• Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005;39:1667-77
   PubMed Web of Science ®Google Scholar
• Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: clinical efficacy, safety, and economics. Ann Pharmacother 2005;39:1844-51
   PubMed Web of Science ®Google Scholar
• Stress ulcer disease (SUD) prophylaxis (2ac_ICU-2 SUD.pdf) in specifications manual for National Hospital Quality Measures – ICU. 2005. Available from: www.jointcommission.org/national_hospital_quality_measures_-_icu/ [Last accessed 10 December 2012]
   Google Scholar
• Dellinger P, Levy MH, Rhodes A, et al. Surviving sepsis campaign: International guideline for the management of severe sepsis and septic shock. Crit Care Med 2013;41:580-637
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2013;41:1-13
   PubMedGoogle Scholar
• Guillamondegui OD, Gunter OL Jr, Bonadies JA, et al. Practice management guidelines for stress ulcer prophylaxis. Eastern Association for the Surgery of Trauma; Chicago, IL, USA: 2008. p. 1-24
   Google Scholar
• Lam NP, Phuong-Dung TL, Crawford SY, et al. National survey of stress ulcer prophylaxis. Crit Care Med 1999;27:98-103
   PubMedGoogle Scholar
• Law JK, Andrews CN, Enns R. Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use. Gastrointest Endosc 2009;69:3-9
   PubMedGoogle Scholar
• Afif W, Alsulaiman R, Martel M, Barkun AN. Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther 2007;25:609-15
   PubMedGoogle Scholar
• Kaplan GG, Bates D, McDonald D, et al. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol 2005;3:1207-14
   PubMedGoogle Scholar
• Lee EY, Brotz C, Greenwald D. Cost and characteristics of intravenous proton pump inhibitor use and misuse in a tertiary care hospital. Am J Gastroenterol 2003;98:S54
   Google Scholar
• Johnson DA. Alternative dosing for PPI therapy: rationale and options. Rev Gastroenterol Disord 2003;3(Suppl 4):S10-15
   Google Scholar
• Colombet I, Sabatier B, Gillaizeau F, et al. Long-term effects of a multifaceted intervention to encourage the choice of the oral route for proton pump inhibitors: an interrupted time-series analysis. Qual Saf Health Care 2009;18:232-5
   PubMedGoogle Scholar
• Olsen KM, Devlin JW. Comparison of enteral and intravenous lansoprazole pharmacodynamic response in critically ill patients. Aliment Pharmacol Ther 2008;28:326-33
   PubMedGoogle Scholar
• Metz DC, Fulda G, Olsen KM, et al. Rapid onset of intragastric acid control with intravenous esomeprazole in critically ill patients. Curr Med Res Opin 2010;26:1141-8
   PubMed Web of Science ®Google Scholar
• Phillips JO, Olsen KM, Rebuck JA, Metzler MH. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 200l;96:367-72
   PubMedGoogle Scholar
• Olsen KM, Bergman KL, Rebuck JA, et al. Pharmacokinetics and pharmacodynamics of omeprazole in critically ill pediatric liver/intestinal transplant patients. Pediatr Crit Care Med 2001;2:232-7
   PubMedGoogle Scholar
• Kuper KM. Intravenous to oral therapy conversion. In: Murdaugh LB, editor. Competence assessment tools for health-system pharmacies. 4th edition. American Society of Health-System Pharmacists; MD, USA: 2008. p. 349-51
   Google Scholar
• Sharma VS, Peyton B, Spears T, et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000;14:887-92
   PubMedGoogle Scholar
• Lasky MJ, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-33
   PubMed Web of Science ®Google Scholar
• Phillips JO, Metzler MH, Palmieri TL, et al. A prospective study of simplified omeprazole suspension for the prophyalxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800
   PubMedGoogle Scholar
• Phillips JO, Metzler MH, Huckfeldt RE, Olsen KM. A multicenter, prospective, randomized clinical trial of continuous IV ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcer (abstract). Crit Care Med 1998;26:A101
   PubMed Web of Science ®Google Scholar
• Song JC, Quercia RA, Fan C, et al. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm 2001;58:689-94
   PubMedGoogle Scholar
• Pisegna JR. Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 2001;32:27-32
   PubMed Web of Science ®Google Scholar
• Freston JW, Kisicki J, Palmer BL, et al. Oral vs intravenous (IV) lansoprazole are therapeutically equivalent in suppressing gastric acid secretion. ACG 2002;Abstracts S51
   Google Scholar
• Tsai Wl, Poon SK, Yu HK, et al. Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients. Aliment Pharmacol Ther 2000;14:123-7
   PubMedGoogle Scholar
• Phillips JO, Olsen KM, Rebuck JA, et al. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 200l;96:367-72
   PubMedGoogle Scholar
• Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension: a liquid formulation of lansoprazole effectively suppresses intragastric acidity when administered through a gastronomy. Am J Gastroenterol 1999;94:1813-17
   PubMedGoogle Scholar
• Doan TT, Wang Q, Griffin JS, et al. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health-Syst Pharm 2001;58:1512-19
   PubMedGoogle Scholar
• Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004;19:1211-15
   PubMed Web of Science ®Google Scholar
• Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health-Syst Pharm 1999;56(Suppl):S18-21
   Google Scholar
• Armstrong D, Bair D, James C, et al. Oral esomeprazole vs intravenous pantoprazole: à comparison the effect of intragastric pH in healthy patients. Aliment Pharmacol Ther 2003;18:705-11
   PubMed Web of Science ®Google Scholar
• Taubel JJ, Sharma VK, Chui YL, et al. A comparison of simplified lansorprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-hour intragastric pH. Aliment Pharmacol Ther 2001;11:1807-17
   Google Scholar
• White CM, Kalus JS, Quercia R, et al. Delivery of esomeprazole magnesium enteric-coated pellets though small caliber and standard nasogastric tubes and gastronomy tubes in vitro. Am J Health Syst Pharm 2002;59:2085-8
   PubMed Web of Science ®Google Scholar
• Dentinger PJ, Swenson CF, Anaizi NH. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm 2002;59:953-6
   PubMed Web of Science ®Google Scholar
• Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol 2010;16:982-6
   PubMedGoogle Scholar
• Nissen SW, Olsen KM. Selection of proton pump inhibitors for formulary inclusion: making decisions based on appropriate criteria. Dis Manag Health Outcomes 2007;15:289-98
   Google Scholar
• Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29
   PubMed Web of Science ®Google Scholar
• Red Book: Pharmacy's Fundamental Reference, 114th edition, 2010: p. 524, 609, 625,626, 642,683,684, 697,698,713
   Google Scholar
• Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med 2003;163:2585-9
   PubMed Web of Science ®Google Scholar
• Colombet I, Sabatier B, Gillaizeau F, et al. Long-term effects of a multifaceted intervention to encourage the choice of the oral route for proton pump inhibitors: an interrupted time-series analysis. Qual Saf Health Care 2009;18:232-5
   PubMedGoogle Scholar
• Sallach-Ruma R, Nieman J, Sankaranarayanan J, Reardon T. Correlates and economic and clinical outcomes of an adult IV to PO antimicrobial conversion program at an Academic Medical Center in Midwest United States. J Pharm Pract 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):141-51
   PubMed Web of Science ®Google Scholar
• Woerkom MV, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):125-30
   PubMed Web of Science ®Google Scholar
• MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014;174(4):564-74
   PubMed Web of Science ®Google Scholar